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regimen. Randomization to a new oral antithrombotics was associated with a significantly
increased risk of major bleeding (OR, 1.99; 95% CI, 1.65 to 2.39).
Conclusions: In patients with ACS, the addition of new oral antithrombotic agent to
standard antiplatelet therapy significantly reduced the primary composite end point but
significantly increased the risk of major bleeding.
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Background: Aspirin and statin therapy are primary treatment strategies in patients with
cardiovascular disease. Heightened urinary 11-dehydrothromboxane B2(11-dTxB2) lev-
els have been associated with an increased risk of adverse cardiovascular events. The aim
of the study was to determine the effect of statin therapy on 11-dTxB2 levels in patients
undergoing coronary angiography on 325 mg aspirin.
Methods: Urinary 11-dTxB2 was measured in patients prior to coronary angiography
with (n155) and without (n95) statin therapy. Lipoproteins by vertical density gradient
ultracentrifugation technique and thrombin-induced platelet-fibrin clot strength(TIP-FCS),
a marker for cardiovascular events by thrombelastography, were also measured. The dose
dependent effect of statin therapy was analyzed according to atorvastatin equivalent dose,
categorized as: 5-10mg, 20-40mg, 80mg.
Results: Baseline demographics and cardiac risk factors were similar between groups.
Statins significantly reduced urinary 11-dTxB2 levels in a dose dependent manner
(Figure). There was a significant relation between quartiles of 11-dTxB2 and TIP-
FCS,(p0.05 for ANOVA). Patients on statin therapy had significantly lower levels of
LDL, triglycerides, VLDL, atherox and apo B100 (p0.005 for all). However, Urinary
11-dTxB2 did not correlate with lipids and lipoproteins measurements.
Conclusions: This is the first study to demonstrate the dose dependent response of statin
therapy on urinary 11-dTxB2 levels, independent of lipid lowering effects.Clinical
outcome studies are required to determine the utility of this novel marker for optimizing
statin therapy.
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Background: Fish Oil supplementation may have anti-atherosclerotic effects by reducing
triglycerides, improving endothelial function, and reducing inflammation. However,
inconsistent results have been reported on the effects of fish oil on platelet function. We
aimed to determine if fish oil supplementation reduced the atherothrombotic risk profile
by measuring lipids and thrombogenic factors simultaneously.
Methods: Patients with suspected coronary artery disease with (n79) and without
(n324) fish oil supplementation were enrolled in the Multi-Analyte, Thrombogenic, and
Genetic Markers of Atheroclerosis (MAGMA) study. The lipid profile was determined by
vertical density gradient ultracentrifugation technique, and thrombogenicity by thrombe-
lastography immediately prior to elective coronary angiography. Urinary 11-
dehydrothromboxane B2 and AtherOx were performed by immunoassay. ADP and collagen-
induced platelet aggregation were measured in aspirin	 clopidogrel- treated patients.
Results: Baseline demographics and cardiac risk factors were similar between groups.
Fish oil supplementation was associated with significantly lower triglycerides, VLDL,
remnant lipoproteins, and AtherOx levels and increased HDL levels (p0.05). Among
patients on aspirin 	 clopidogrel therapy, fish oil supplementation was associated with
lower collagen-induced platelet aggregation (p0.05, Table).
No Fish Oil
(n324)
Fish Oil
(n79)
p-valueMean  SD Mean SD
Lipid Profile (mg/dL)
Total cholesterol 16138 16252 0.85
Total low density lipoprotein 9330 9443 0.87
Total high density lipoprotein 4412 4917 0.03
Total very low density lipoprotein 2213 196 0.02
Triglycerides 12690 10357 0.05
Remnant lipoproteins 24.311 21.07.6 0.02
Thrombogenicity Profile
AtherOx (mg/dL) 0.420.48 0.290.27 0.05
Lipoprotein (a) (mg/dL) 8.66.3 8.46.0 0.82
11-dehydrothromboxane B2 (pg/
mg creatinine)
16331636 13301520 0.25
Clotting index 0.72.6 0.53.2 0.12
MAKH (mm) 66.66.1 65.54.5 0.21
R (min) 7.92.3 7.42.9 0.12
20uM ADP-induced aggregation 5220 4621 0.2
4ug/mL collagen-induced
aggregation
4822 3822 0.05
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Conclusions: This is the first study to simultaneously examine the influence of fish oil
supplementation on lipid and thrombogenicity profiles. Our study supports prior evidence
of an improved lipid profile and suggests an enhancement of the anti-platelet effects of
DAPT. Prospective studies are needed to determine the contribution of each of these
effects of fish oil supplementation on thrombotic event occurrence.
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Background: Anti-anginal medications (AAM) directed at lowering the rate pressure
product (RPP) are prescribed to patients undergoing percutaneous coronary intervention
(PCI) for chronic ischemic heart disease (CHD) to reduce repeat revascularization (RR).
Methods: We analyzed the VA VISN17 PCI data from 2008-2011 to evaluate the impact
of AAM score (Table 1) and RPP control on RR.
Results: From 1078 patients, we identified 530 stable angina patients with 12-month
post-PCI follow-up. Mean RPP was 9542.5102.1 (SE) and AAM score 2.810.11
(beta-bockers 96%, calcium channel blockers 36.4%, nitrates 47% and ranolazine 3.4%).
Patients requiring RR had mean AAM score of 3.640.24 and RPP of 9062.9188.7
compared to those without RR (AAM score2.710.14, RPP9472.5120.0; p0.02
for AAM score; p0.07 for RPP comparisons). AAM score2.5 (median) and
RPP9080 (median) were not associated with a lower need for RR (OR for AAM
score0.71, 95% CI: 0.43–1.15, p0.30; OR for RPP0.95, 95% CI: 0.58–1.55,
p0.86, Figure 1), as was a AAM score85th percentile, after adjusting for age, diabetes
mellitus, chronic kidney disease and prior coronary artery disease (OR2.03: 95% CI:
0.99-4.16, p0.06).
Conclusions: Intensive AAM and lowering of RPP alone did not reduce the need for RR
in CHD patients undergoing PCI.
Table 1: Scoring of Anti-Anginal Medical Treatment
Drug Category
(maximum
points/category
 4) Any
ranolazine use
is an additional
1 point. Drug
Low
Dose/
day
(1 point)
Medium
Dose/day
(2 points)
High Dose/
day
(3 points)
Very
High/day
(4 points)
Calcium Channel
Blockers
Amlodipine 5mg 5.0–9.9mg 10mg 10mg
Felodipine 5mg 5.0–9.9mg 10mg 10mg
Isradipine 10mg 10.0–14.9mg 15-19.9mg 19.9mg
Nicardipine 60mg 60–119.9mg 120mg 120mg
Nifedipine 60mg 60–89.9mg 90mg 90mg
Verapamil 240mg 240–359.9mg 360mg 360mg
Diltiazem 240mg 240–359.9mg 360mg 360mg
Beta Blockers Atenolol 50mg 50–99.9mg 100mg 100mg
Bisoprolol 5mg 5–9.9mg 10mg 10mg
Carvedilol 12.5mg 12.5–24.9mg 25–49.9mg 50mg
Labetalol 400mg 400–799.9mg 800mg 800mg
Metoprolol 50mg 50–99.9mg 100–199.9 200mg
Nadolol 80mg 80–159.9mg 160mg 160mg
Nitrates Nitroglycerin
SR
7.5mg 7.51–19.4mg 19.5–39mg 39mg
Nitroglycerin
patch
0.2mg 0.4mg 0.6mg 0.8mg
Isosorbide
dinitrate
60mg 60–89.9mg 90–119mg 119mg
Isosorbide
mononitrate
30mg 60mg 90–119mg 119mg
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Background: We investigated whether statin therapy and high-sensitivity C-reactive
protein (hs-CRP) levels were associated with long term clinical outcomes in acute
myocardial infarction (AMI) patients presenting atrial fibrillation (AF).
Methods: 852 AMI patients (mean age  70.3  12.2 years, 565 males) who were
presented AF on electrocardiogram in arrival at emergency room from the Korean Acute
Myocardial Registry (KAMIR) were divided into two groups; the low hs-CRP group
(hs-CRP  2 mg/dl, n  339, 67.8  12.8 years, 239 males) or the high hs-CRP group
(hs-CRP 2mg/dl, n  513, 71.9  11.5 years, 326 males). We evaluated the incidence
of MACEs during in hospital period and one year clinical follow up according to the statin
therapy in each groups.
Results: Analysis according to level of hs-CRP value of 2.0mg/L, statin treatment had an
effect on reduced the incidence of MACEs in both the low hs-CRP group [statin
group:7.6%, non statin group:14.9%, p0.003] and the high CRP group [statin group:
13.7%, non statin group: 30.2%, p0.001]. In a Cox regression analysis after adjustment
of potential confounder, the statin treatment was a significant predictor of MACEs in low
hs-CRP group [p0.045, HR:0.50,95% CI:0.26-0.98], however in the high hs-CRP
group, statin treatment showed more potent effect on reduction of MACEs risk (p0.001,
HR:0.44, 95% CI:0.29-0.66).
Conclusions: Statin treatment can improve clinical outcome in AMI patients with
presenting AF. These effects were more prominent in patients had high level of hs-CRP,
probably associated with anti-inflammatory effect of statin.
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